Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01181271 · ClinicalTrials.gov registry record · Phase 2
Tandem Auto-Allo Transplant for Lymphoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01181271: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01181271 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01181271, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in an attempt to induce a graft versus lymphoma effect. This study will assess the feasibility, safety and efficacy of the combination of autologous stem cell transplantation followed by non-myeloablative transplantation for patients with poor-risk aggressive lymphoma.
Interventions
- DRUG Busulfan (conditioning for AUTO transplant)
- DRUG Etoposide (conditioning for AUTO transplant)
- DRUG Cyclophosphamide (conditioning for AUTO transplant)
- DRUG Mesna (prior to AUTO transplant)
- OTHER autologous (auto) peripheral blood stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01181271
The ClinicalTrials.gov registry entry for NCT01181271 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Busulfan (conditioning for AUTO transplant) is the first listed.
NCT01181271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01181271 about?
NCT01181271 is a clinical study titled "Tandem Auto-Allo Transplant for Lymphoma". Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in an attempt to induce a graft versus lymphoma effect. This study will as...
What is the current status of trial NCT01181271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2010-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01181271?
The interventions under investigation include: Busulfan (conditioning for AUTO transplant) (DRUG), Etoposide (conditioning for AUTO transplant) (DRUG), Cyclophosphamide (conditioning for AUTO transplant) (DRUG), Mesna (prior to AUTO transplant) (DRUG), autologous (auto) peripheral blood stem cell transplantation (OTHER).
Who is sponsoring clinical trial NCT01181271?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.